Ignite Creation Date:
2025-12-25 @ 5:09 AM
Ignite Modification Date:
2026-02-11 @ 8:38 PM
Study NCT ID:
NCT01242527
Status:
COMPLETED
Last Update Posted:
2016-08-04
First Post:
2010-11-15
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Epanova® for Lowering Very High Triglycerides
Sponsor:
AstraZeneca
Organization:
Study Overview
Official Title:
Efficacy and Safety of Epanova® (Omefas) in Severe Hypertriglyceridemia
Status:
COMPLETED
Status Verified Date:
2016-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
EVOLVE
Brief Summary:
The primary objective of the study is to determine the efficacy of Epanova (omefas) compared to placebo in lowering serum triglycerides in subjects with severe hypertriglyceridemia.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: